Skip to main content

Table 4 Immune responses and clinical outcomes in 8 patients

From: A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

ID No. DC injection DTH CD4 T cell response CD8 T cell response MDSCs* Tregs* IL-8 Change in Target Lesions (%) Clinical Response PFS§(d) OS§(d) Prognosis
1802 6 + + + decreased decreased low −25.4 SD 173 339 Dead
1803 6 - + - decreased decreased low 0 SD 200 353 Dead
1806 6 - - - decreased no change high −18.4 N.A. 100 100 Dead
1808 6 - - - no change increased high −5.4 SD 155 193 Dead
1812 6 - - + no change no change low 30.3 PD# 101 1140|| Alive
1814 12 + + + decreased decreased low −100 CR 347 1127|| Alive
1817 6 - - - no change increased high −27.8 PD** 88 206 Dead
1823 12 + + + decreased no change high −35.3 PR 342|| 342|| Alive
  1. PFS, progression free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
  2. *Compared to the baseline.
  3. High or low is defined as more or less than 60 pg/ml in sera.
  4. 4wks after last injection.
  5. §From the registration (days).
  6. Withdrawn from the study by sudden hypertensive cerebral hemorrhage.
  7. ||A censored case due to the termination of the study.
  8. #After surgical removal of target lesion (LN metastasis), no recurrence was observed.
  9. **Though target lesion became smaller, accumulation of pleural effusion was increased.